SARAH DAROUSE: Open Payments
NPI 1801380829 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,081 in 105 payments from 19 companies in 2025. Trend: 2023 $1,383 · 2024 $2,012 · 2025 $2,081
Food & beverage: $2,081
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 38 | $528 |
| GENZYME CORPORATION | 14 | $431 |
| AstraZeneca Pharmaceuticals LP | 13 | $274 |
| Grifols USA, LLC | 4 | $104 |
| Verona Pharma, Inc. | 4 | $83 |
| Insmed, Inc. | 4 | $77 |
| Actelion Pharmaceuticals US, Inc. | 3 | $77 |
| REVANCE THERAPEUTICS, INC. | 2 | $76 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $71 |
| Merck Sharp & Dohme LLC | 3 | $61 |
Products named: DUPIXENT, TRELEGY ELLIPTA, NUCALA, FASENRA, Prolastin-C Liquid, Ohtuvayre, Arikayce, TEZSPIRE.
Industry payments across LA — which companies pay providers there.
